Business View: No level playing field in the game of French cricket

Date: 8 August 2005
Source: Independent

Date: 8 August 2005

It's just not cricket. First those Frenchies contact a chap on the first day of the Lord's Test and try to persuade him to sell his company.

Then, after telling them they've not put enough euros on the table, they go and launch a hostile bid just as the second Test is about to start.

Now to be fair to Saint-Gobain, the French glass maker seems almost embarrassed about having to go over the heads of the directors of BPB with its £3.7bn offer. Its awfully charming chief operating officer, Pierre-André de Chalendar, has been given the task of selling the deal over here, and he seems most apologetic about how things have turned out. "We have the greatest respect for the BPB management," he says. "I wish there was another word to use than 'hostile'." And, he admits: "We should have known more about cricket."

Still, should we complain? It may only be the plasterboard market. And the offer price is unlikely to go above the £4bn mark. But this is still a hostile bid for a FTSE 100 company. And you don't get many of them. Indeed, you probably have to go back to Lafarge's capture of Blue Circle to see a hostile bid for a FTSE 100 company succeed. And what did that offer have in common with this? The sector was building materials. And the bidder was French.

"What's the problem with that?" you may ask. If our French cousins want to pay more for a British company than our fine institutional shareholders think it is worth, then it is their look-out. A year ago, BPB shares were languishing at half their Friday close of 735p, and they were only around 520p before the Ashes started. In their classic way, the City investors, who thought BPB was pricey at 520p, now think it is too cheap at 735p. But if Gobain puts 760p or so on the table, these stout yeomen will suddenly gain a taste for Brie and baguettes.

If Gobain does win BPB, there will be two awful ironies.

The first is that Gobain is only in a position to bid for BPB now because it feels that it is close to drawing a line under its legacy of asbestosis claims in the US - a problem that BPB was almost unique in its industry in having avoided. The French are confident because a bill is being presented to the US Congress proposing a $140bn settlement of all outstanding claims. However, the latest noises coming from Capitol Hill are that three Democratic senators on the committee framing the bill fear that $140bn may not be enough money. So Gobain's confidence may be premature.

More information through the Independent source link......

600450 Business View: No level playing field in the game of French cricket glassonweb.com

See more news about:

Others also read

Emirates Glass, a Dubai Investment subsidiary, has won a major contract to supply 140,000 square meters of its premium glass to the prestigious development on the Palm Jumeirah, reaffirming its already established reputation as the single most prominent company in the entire regional glass industry.The deal was announced during the company's participation in the prestigious Big 5 show, the largest annual venue for the entire Middle-East glass contracting industry.
Packagers such as the UK's Rexam and private equity firms are set to vie for pump-sprayer business Calmar, which France's Saint-Gobain (SGOB.
Isra Vision Systems AG supplier of machine vision systems, has successfully improved its market position in display glass inspection with a major order totalling 1.8 Mio Euro.
Jain Scientific Glass Works, manufacturers of glassware for laboratories, is importing glass as raw material from China, which was much cheaper than the local product and abundantly available.
The National Lime & Stone Co. will discontinue production of calcined lime early next month at its Carey plant, the company CEO announced Thursday.
The following stocks are moving in Japanese markets today. Prices are as of 12:55 p.m. at the Tokyo Stock Exchange. Stock symbols are in parentheses after company names.

Add new comment